- A Case of Late-Onset De Novo Huntington's Disease Diagnosed via 18 F-FDG PET
-
Joo JY, Chae SY, Kim JS, Kim HJ
- KMID: 2560835
- Dement Neurocogn Disord.
- 2024 Oct;23(4):245-247.
- doi: 10.12779/dnd.2024.23.4.245
-
- CITED
-
- Close
- SHARE
-
- Close
- Differential Validity of K-MoCA-22 Compared to K-MoCA-30 and K-MMSE for Screening MCI and Dementia
-
Kim H, Yu KH, Kang Y
- KMID: 2560834
- Dement Neurocogn Disord.
- 2024 Oct;23(4):236-244.
- doi: 10.12779/dnd.2024.23.4.236
Background and Purpose: Since the onset of the coronavirus disease 2019 pandemic, the Telephone-Montreal Cognitive Assessment (T-MoCA) has gained popularity as a remote cognitive screening tool. T-MoCA includes items from... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Choline Alfoscerate on the Progression From Mild Cognitive Impairment to Dementia: Distributed Network Analysis of a Multicenter Korean Database Using a Common Data Model
-
Pyun JM, Lee I, Lee K, Kim Mh, Park C, Yang HJ
- KMID: 2560831
- Dement Neurocogn Disord.
- 2024 Oct;23(4):202-211.
- doi: 10.12779/dnd.2024.23.4.202
Background and Purpose: Choline alfoscerate (CA) is an acetylcholine precursor known for its beneficial effect on cognition in patient with Alzheimer’s disease dementia (ADD). However, there is little evidence of its... -
- CITED
-
- Close
- SHARE
-
- Close
- Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD): A Cohort for Dementia Research and Ethnic-Specific Insights
-
Jang H, Shin D, Kim Y, Kim KW, Lee J, Kim JP, Kim HJ, Cho SH, Kim SE, Na DL, Seo SW, obotKRSG
- KMID: 2560832
- Dement Neurocogn Disord.
- 2024 Oct;23(4):212-223.
- doi: 10.12779/dnd.2024.23.4.212
Background and Purpose: Dementia, particularly Alzheimer’s disease, is a significant global health concern, with early diagnosis and treatment development being critical goals. While numerous cohorts have advanced dementia research, there... -
- CITED
-
- Close
- SHARE
-
- Close
- Revolutionizing Alzheimer’s Diagnosis and Management: The Dawn of Biomarker-Based Precision Medicine
-
Kwon HS, Yu HJ, Koh SH
- KMID: 2560830
- Dement Neurocogn Disord.
- 2024 Oct;23(4):188-201.
- doi: 10.12779/dnd.2024.23.4.188
Alzheimer’s disease (AD), a leading cause of dementia, presents a formidable global health challenge intensified by the aging population. This review encapsulates the evolving landscape of AD diagnosis and treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- Lecanemab: Appropriate Use Recommendations by Korean Dementia Association
-
Park KH, Kim GH, Kim CH, Koh SH, Moon SY, Park YH, Seo SW, Yoon B, Lim JS, Kim BC, Kim HJ, Na HR, Shim Y, Yang Y, Lee CN, Rhee HY, Jung S, Jeong JH, Choi H, Yang DW, Choi SH
- KMID: 2560829
- Dement Neurocogn Disord.
- 2024 Oct;23(4):165-187.
- doi: 10.12779/dnd.2024.23.4.165
Lecanemab (product name Leqembi ® ) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's... -
- CITED
-
- Close
- SHARE
-
- Close
- Development of the Diagnostic Matrix of the Seoul Cognitive Status Test, Compared to Traditional Paper-andPencil Neuropsychological Tests
-
Na S, Kim YJ, Kim SE, Jung NY, Kim SJ, Kim HJ, Shin JS, Na DL, Seo SW, Kim Y, Lee ES
- KMID: 2560833
- Dement Neurocogn Disord.
- 2024 Oct;23(4):224-235.
- doi: 10.12779/dnd.2024.23.4.224
Background and Purpose: We aimed to develop the diagnostic matrix of the Seoul Cognitive Status Test (SCST) and compare its performance with traditional paper-and-pencil neuropsychological tests, including the Seoul Neuropsychological... -
- CITED
-
- Close
- SHARE
-
- Close
